Endothelin 1(human) peptide

Endothelin 1(human) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-CSCSSLMDKECVYFCHLDIIW-OH

H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH

21

95.35%

C₁₀₉H₁₅₉N₂₅O₃₂S₅

2491.89

Synthetic

Powder

Endothelin-1 is one of three isoforms of human endothelin (ET-1). It is a potent vasoconstrictor that is expressed by many cell types, with the vascular endothelium being most prominent. ET-1 is also produced by many tissues, including kidney, brain and lung among others. Antagonists of ET-1 receptors are used to treat pulmonary hypertension by inhibiting pulmonary vascular constriction thereby decreasing pulmonary vascular resistance.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.